Bcl-xl Protac - A Safer More Effective Antitumor Agent

B-cell lymphoma extra large (BCL-XL) is a well validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as ABT263, as safe and effective anticancer agents. We creatively used proteolysis-targeting chimera (PROTAC) technology to generate BCL-XL PROTACs to overcome the on-target toxicity of ABT263, resulting in a clinical drug candidate, DT2216, that has the potential to be developed as a safe first-in-class anticancer agent targeting BCL-XL.

Daohong Zhou, MD
Professor, UT Health San Antonio
Associate Director for Drug Development, Mays Cancer Center
Director, Center for Innovative Drug Discovery